Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-11-01
|
| Series: | Journal of Translational Medicine |